Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023)
Exelixis' (EXEL) quarterly Non-Current Deffered Revenue came in at $6.7 million in Q2 2023, down 6.73% year-on-year from $7.2 million in Q2 2022, and up 6.75% quarter-over-quarter from $6.3 million in Q1 2023.
Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023) Analysis & Trends
Exelixis' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $6.7 million for Q2 2023.
- On a quarterly basis, Non-Current Deffered Revenue fell 6.73% year-over-year to $6.7 million in Q2 2023; TTM through Jun 2023 was $6.7 million, a 6.73% decrease from a year earlier, with the FY2022 full-year figure at $6.6 million, down 24.68% from the prior year.
- Non-Current Deffered Revenue rose to $6.7 million in Q2 2023 per EXEL's latest filing, from $6.3 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $16.6 million in Q2 2019 and bottomed at $3.8 million in Q1 2021.
- The 5-year median for Non-Current Deffered Revenue is $8.4 million (2019), against an average of $9.3 million.
- Across the five-year window, Non-Current Deffered Revenue soared 579.01% in 2019 and sank 58.51% in 2020, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $15.4 million in 2019, then plunged by 39.47% to $9.3 million in 2020, then slipped by 6.25% to $8.7 million in 2021, then fell by 24.68% to $6.6 million in 2022, then rose by 2.16% to $6.7 million in 2023.
- Per Business Quant, the three latest EXEL Non-Current Deffered Revenue figures stand at $6.7 million (Q2 2023), $6.3 million (Q1 2023), and $6.6 million (Q4 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 6.72 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Dec 30, 2022 | 6.58 Mn |
| Sep 30, 2022 | 6.49 Mn |
| Jul 1, 2022 | 7.21 Mn |
| Apr 1, 2022 | 8.04 Mn |
| Dec 31, 2021 | 8.74 Mn |
| Oct 1, 2021 | 9.44 Mn |
| Jul 2, 2021 | 8.58 Mn |
| Apr 2, 2021 | 9.76 Mn |
| Jan 1, 2021 | 3.76 Mn |
| Oct 2, 2020 | 9.32 Mn |
| Jul 3, 2020 | 15.00 Mn |
| Apr 3, 2020 | 14.13 Mn |
| Jan 3, 2020 | 6.60 Mn |
| Sep 27, 2019 | 15.40 Mn |
| Jun 28, 2019 | 16.63 Mn |
| Mar 29, 2019 | 8.32 Mn |
| Dec 28, 2018 | 15.90 Mn |
| Sep 28, 2018 | 2.27 Mn |